Newsbenzinga
AbbVie Touts Positive Data For Multiple Myeloma Drug
· Published
Article summary
AbbVie reports positive Phase 3 results for etentamig, showing higher response rates and improved survival in multiple myeloma patients.
An excerpt from the original article.
Comments —
Loading comments…